News summaryHelus Pharma Investor RelationsNov 16, 2026, 12:00 PM
Helus Pharma reported fiscal Q2 2027 results and business updates
On Nov. 16, 2026, Helus reported $171.1 million cash as of Sept. 30, 2026; quarterly net loss was $103.1 million vs. $33.7 million a year earlier, and operating cash use was $35.3 million vs. $34.5 million. It appointed Michael Halstead CEO, reported APPROACH enrollment complete, and said the HLP004 Phase 2 GAD study is expected to start Q1 2027, enrolling about 144 participants.